Key facts
as of Sep 2026- OrganOx’s last known valuation is $1.5B (Oct 2025).
- It has raised $237.7M; the latest was Merger/Acquisition ($1.5B) in Oct 2025.
- 1 institutional filer reports fund marks on OrganOx across 2 filings.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for OrganOx
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in OrganOx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 2 fair-value marks on OrganOx between Jan 2026 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for OrganOx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OrganOx
Developer and manufacturer of organ preservation and transplantation devices designed to reduce liver decay. The company specializes in making products based on warm conservation that seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells and nutrition, enabling healthcare providers to prevent the deterioration of the organ by producing bile, metabolizing glucose and maintaining a physiological pH level.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Employees
- 199
- Website
- organox.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)